- Home
- PHGE vs SPRB Comparison
PHGE vs SPRB Comparison
Compare PHGE & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- SPRB
- Stock Information
- Founded
- PHGE 2015
- SPRB 2014
- Country
- PHGE Israel
- SPRB United States
- Employees
- PHGE N/A
- SPRB N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- PHGE Health Care
- SPRB Health Care
- Exchange
- PHGE Nasdaq
- SPRB Nasdaq
- Market Cap
- PHGE 13.3M
- SPRB 15.7M
- IPO Year
- PHGE N/A
- SPRB 2020
- Fundamental
- Price
- PHGE $0.60
- SPRB $0.35
- Analyst Decision
- PHGE Strong Buy
- SPRB Hold
- Analyst Count
- PHGE 2
- SPRB 7
- Target Price
- PHGE $13.50
- SPRB $2.17
- AVG Volume (30 Days)
- PHGE 126.6K
- SPRB 350.6K
- Earning Date
- PHGE 04-02-2025
- SPRB 03-21-2025
- Dividend Yield
- PHGE N/A
- SPRB N/A
- EPS Growth
- PHGE N/A
- SPRB N/A
- EPS
- PHGE N/A
- SPRB N/A
- Revenue
- PHGE N/A
- SPRB $7,101,000.00
- Revenue This Year
- PHGE N/A
- SPRB N/A
- Revenue Next Year
- PHGE N/A
- SPRB N/A
- P/E Ratio
- PHGE N/A
- SPRB N/A
- Revenue Growth
- PHGE N/A
- SPRB N/A
- 52 Week Low
- PHGE $0.48
- SPRB $0.34
- 52 Week High
- PHGE $6.30
- SPRB $5.53
- Technical
- Relative Strength Index (RSI)
- PHGE 35.68
- SPRB 33.49
- Support Level
- PHGE $0.60
- SPRB $0.34
- Resistance Level
- PHGE $0.69
- SPRB $0.37
- Average True Range (ATR)
- PHGE 0.11
- SPRB 0.03
- MACD
- PHGE -0.04
- SPRB -0.01
- Stochastic Oscillator
- PHGE 3.10
- SPRB 12.45
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).